As in the general population, the spectrum of ventricular arrhythmias in patients with congenital heart disease (CHD) ranges from ventricular ectopics to nonsustained ventricular tachycardia (VT), sustained monomorphic VT, polymorphic VT and ventricular fibrillation (VF). Accordingly, the clinical manifestations can be variable and include palpitations, syncope, heart failure secondary to tachycardiomyopathy, or sudden cardiac death (SCD) from malignant ventricular arrhythmias. The incidence of sudden cardiac death in the CHD population in general is estimated to be about 0.1% per year [2] . Sudden cardiac death (20%) and heart failure (30%) account for nearly half of all late deaths in mixed cohorts of children and adults with CHD [3] . Although nonsustained VT has not been linked to sudden death in a heterogeneous population of patients with CHD, it has been associated with inducible and clinical ventricular tachyarrhythmias in patients with tetralogy of Fallot (TOF) [4] .
This article provides an overview of the electrophysiological treatments of ventricular arrhythmias in the setting of congenital heart disease.
Arrhythmogenic milieu in CHD patients
Underlying CHD often results in pathological ventricular hypertrophy, dilatation and/or fibrosis of either or both ventricles, and heart failure. As a result, in much the same way as with other diseases leading to ventricular remodelling and heart failure, the majority of sus- In patients with CHD, the burden of the original cardiac malformation is frequently combined with the sequellae of reparative surgery, and this combination increases these patients' vulnerability to arrhythmias.
After reparative surgery, the presence of surgical scars and prosthetic and patch material modifies mechanical and electrical properties of the ventricles by producing large inexcitable areas with adjoining, relatively delimited isthmuses of slowed conduction. This combination, as is well known at the atrial level, lends itself readily to monomorphic reentrant ventricular arrhythmias. Accordingly, in patients with repaired TOF and an ICD, more than 80% of all treated ventricular arrhythmias have been monomorphic VTs [5, 6] .
Similarly, monomorphic VTs have also been reported in patients with d-TGA and ventricular septal defect (VSD) closure or repaired outflow tract obstruction.
The presence of iatrogenic scars, however, does not exclude the occurrence of polymorphic VT/VF in these patients; since residual defects (VSD or outflow obstruction) or postsurgical sequelae (e.g., pulmonary regurgitation) still produce ventricular hypertrophy, fibrosis and dilatation and heart failure, which is thought to be the substrate for polymorphic VT/VF.
Because of the generally downhill course of the natural history of most severe congenital heart disease states, in particular uncorrected ones, there is a significant time-dependent increased risk of ventricular arrhythmia. Both the underlying disease and the type of surgical/interventional correction can significantly influence this risk. The lifetime estimated risk of ventricular tachycardia ranges from <2% for atrial septal defect to 10-15% for TOF with the caveat that these figures also reflect the average lifespan for patients with these conditions in addition to the disease itself [2] . In the absence of a surgical scar or patch, systemic ventricular dysfunction is the dominant underlying predictor for sudden cardiac death in CHD patients, typically due to polymorphic VT or VF. Compare, for instance, the 7-9% estimated lifetime incidence of VT in d-TGA after atrial switch (with a systemic right ventricle, prone to late failure) with an incidence of <2% for d-TGA after an arterial switch [2] . Recent data indicate that heart failure is on par with or gaining against sudden cardiac death as the chief cause of late death in a mixed CHD population [3] , probably as a consequence of increasing life expectancy and perhaps also of improved management of malignant ventricular arrhythmias. As with other categories of heart disease, the decision to implant an ICD in patients with CHD should factor in overall life expectancy, and the risk of heart failure and comorbidities.
Therapies for ventricular arrhythmias
Therapy for ventricular arrhythmias in the setting of CHD includes specific reparative treatment of the under lying heart disease, and of the residual lesions, control of heart failure and treatment of comorbidities, as well as direct treatment of the ventricular arrhythmias. A case-by-case consultative interaction between electrophysiologists, heart failure specialists and GUCH specialists, as in our institution, can provide the close coordination and specific adjustments required for managing these complex patients.
Direct treatment modalities for ventricular arrhythmias include, of course, antiarrhythmic drugs, cardiac implantable devices including ICDs, and catheter and surgical ablation directed at the arrhythmia mechanism. Cardiac resynchronisation by itself is considered a heart failure management therapy and will not be detailed further here.
How can the electrophysiologist help?
Electrophysiologists can play an important and often a 
Arrhythmia evaluation
Holter monitoring for the detection of nonsustained and sustained ventricular arrhythmias should be con- In CHD patients with significant ventricular arrhythmias, syncope or resuscitated sudden death and who are scheduled for surgery, an EP study should be considered in order to evaluate possible integration of therapy directed at the specific arrhythmia substrate during the surgical repair -intraoperative ablation or incisional lesions (see later). In some CHD patients, particularly those with a surgical ventricular scar, an EP study may also be required to reliably distinguish supra ventricular arrhythmias.
Catheter ablation for ventricular tachycardia
The current state of the art of catheter ablation for VT has evolved considerably, but its efficacy is still limited by the inability to delineate the detailed electrical activation sequence and the complete reentrant circuit of the ventricular arrhythmia, either because it is intramural or more frequently, the "mapping" is precluded by haemodynamic compromise during sustained ventricular arrhythmia. Considerable progress has been made, however, in delineating potential "isthmuses"
("alley-ways" of pronounced slow conduction which play a key role in permitting the existence and stability of reentrant circuits) during sinus rhythm or a paced ventricular rhythm, particularly in patients with other forms of structural heart disease such as ischaemic and nonischaemic cardiomyopathies [10, 11] . These were present in almost all specimens, whereas isthmuses 2 and 4 were observed in only 25 % and 13 %, respectively. In specimens from patients aged ≥5 years at the time of death, isthmus 3 was significantly narrower and thinner with more interstitial and replacement fibrosis than isthmus 1 [13, 14] .
Macro-reentry using these isthmuses is the most frequent mechanism of sustained monomorphic VT in these patients and, depending upon the exit site (right ventricular free wall or septal) can produce different ECG morphologies (e.g., a characteristic QS or QR, respectively, in V1). 
Sudden cardiac death and implantable cardioverter defibrillators in congenital heart disease
The incidence of SCD in repaired CHD is 0.9 per 1000 patient years, which is 25-to 100-fold higher than for the general population [5] .
ICD interrogation in patients with repaired TOF and TGA, implanted for both primary and secondary prevention, has shown that >80% of all ventricular arrhythmias that prompted ICD therapy in repaired TOF and around 50% in TGA patients are fast and monomorphic VT, often with heart rates >200 bpm [8, 9] .
Identifying risk factors in these patients is complicated
by time-and age-dependent changes, such that factors 
Illustrative case
The following history may provide a useful example of many of the issues discussed above in the management of VT in the setting of complex CHD. 2, centre panel), and because of proximity to the His bundle potential, radio frequency lesions were prudently delivered to this region in sinus rhythm ( fig. 3) .
Although a VT similar in morphology to the second VT 
Clinical implications
As in other patients, ventricular arrhythmias are a major cause of morbidity and mortality in patients with CHD. Appropriate diagnosis and specific treat- 
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